Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell linesNuzhat I. Pathan(Biogen (United States)), John C. Byrd(The Ohio State University)BloodNovember 22, 200710.1182/blood-2007-03-082024Cited by 72SaveCiteExport RISWatch citationsRelated PapersCombination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia|Blood|2006|293Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties|The Journal of Immunology|2013|93